Browse the evidence

Obesity involves molecular mechanisms, including metabolic memory and epigenetic modifications, that actively hinder weight loss and promote weight regain.

If you are struggling to lose weight despite diet and exercise, recognize that your body has biological defenses (like metabolic memory and hormonal shifts) that actively work to restore previous weight. This is not a failure of willpower but a known physiological response. Addressing these barriers may require a multidisciplinary approach, potentially including medical interventions, rather than just stricter dieting.

Epigenetic changes, such as DNA methylation and histone modifications, can persist after weight loss and contribute to weight regain.

Weight loss can trigger long-lasting epigenetic changes that make your body more prone to regaining weight. This means maintaining weight loss might require ongoing effort and potentially medical support, as your body's 'default setting' may have shifted.

Adipose tissue dysfunction, characterized by chronic low-grade inflammation and insulin resistance, creates a self-perpetuating cycle that promotes obesity.

Excess fat, especially around the abdomen, is not just inert storage but an active organ that releases inflammatory signals. These signals can cause insulin resistance and further fat storage, creating a cycle that is hard to break without addressing the underlying inflammation.

Rapid and significant weight loss induced by Tirzepatide leads to aesthetic changes, including facial volume loss ('Ozempic face'), skin laxity, and altered collagen structure, which are secondary to fat loss rather than direct drug toxicity.

Significant weight loss can cause your face to look older or saggy due to loss of facial fat. This is a side effect of the weight loss, not the drug itself. Eating enough protein and vitamins (like D and B12) during treatment may help maintain skin health.

GLP-1 receptor agonists may interact with oral systemic cancer therapies by delaying gastric emptying, potentially altering absorption kinetics (time to peak concentration) without necessarily changing total drug exposure.

If you take oral cancer pills along with GLP-1 drugs (like Ozempic), tell your doctor. The GLP-1 drug might slow down how fast your cancer pills are absorbed. This doesn't always mean the treatment won't work, but your doctor needs to know to monitor you closely.

GLP-1 receptor agonist consumption in Brazil is driven by socioeconomic capacity and access rather than epidemiological need, as evidenced by a significant positive correlation with GDP per capita and no correlation with obesity prevalence.

In Brazil, access to GLP-1 drugs like semaglutide is currently determined by your state's economic wealth rather than your obesity rates. Public health policy has excluded these drugs from free coverage, creating a market where only those with higher income can afford them, regardless of medical need.

Semaglutide is the predominant GLP-1 RA in Brazil, driving the majority of sales growth and adverse event reports, with significant off-label use for weight loss.

Semaglutide is the most widely used GLP-1 drug in Brazil. A significant portion of its use is off-label for weight loss, which generates specific adverse event reports and requires careful monitoring.

Oriental Melon Stem Ethanol Extract (CMSE) reduces body weight and fat mass in high-fat diet-induced obese mice by increasing energy expenditure and enhancing brown adipose tissue thermogenesis, independent of calorie intake.

If you are looking for a supplement to support weight management, Oriental Melon Stem Extract (CMSE) shows promise in animal studies for boosting metabolism and burning fat without needing to eat less. The effective dose in mice translates to a high daily intake for humans (~2.3g), which falls within the range of dietary supplements. While not a magic bullet, it may support metabolic health and liver function when combined with a balanced diet.

GLP-1 receptor agonist therapy (semaglutide/tirzepatide) is increasingly driving referrals for post-weight-loss body contouring, with referral volumes growing faster than those from lifestyle modification or bariatric surgery.

If you are using GLP-1 medications like Ozempic or Mounjaro, be aware that rapid weight loss often leads to excess skin. You may need to consult a plastic surgeon for body contouring procedures. This is a common and expected outcome of significant weight loss via these medications.

In type 2 diabetes, worsening chronic glycaemic control (higher HbA1c) shifts endogenous GIP action from insulinotropic to glucagonotropic, strengthening the correlation between GIP and glucagon secretion while weakening its correlation with insulin.

For people with Type 2 Diabetes, the effectiveness of the body's natural GIP response depends heavily on how well blood sugar is controlled. If HbA1c is high, GIP may contribute to higher glucagon (raising blood sugar) rather than helping insulin. This suggests that managing baseline blood sugar is crucial for optimizing natural hormonal responses.

Expanding first-level genetic screening for obesity to include POMC and MC3R genes is necessary to maximize diagnostic yield and identify patients with intermediate susceptibility phenotypes who are missed by standard panels.

If you have obesity and standard genetic tests came back negative, ask your doctor about expanded testing for POMC and MC3R genes. This can reveal if you have a specific biological susceptibility that might affect how your body handles energy, potentially guiding more personalized treatment strategies.

GLP-1 and dual GIP/GLP-1 receptor agonists exert neuropsychiatric effects by modulating central neurotransmitter systems (dopamine, serotonin, GABA, glutamate) and promoting neuroplasticity, potentially treating addiction, depression, and cognitive decline.

GLP-1 and dual agonists (like semaglutide and tirzepatide) do more than just suppress appetite; they interact with brain receptors that regulate mood, reward, and memory. While they are primarily prescribed for diabetes and weight loss, research suggests they may also help with conditions like addiction, depression, and cognitive decline by balancing neurotransmitters like dopamine and serotonin. However, patients should be aware that while serious psychiatric side effects are rare and not consistently linked to the drugs, isolated reports of mood changes exist, so monitoring mental health is recommended.

GLP-1RAs are associated with rare but serious adverse events including acute pancreatitis, gallbladder disease, and potential worsening of diabetic retinopathy, though causal relationships for some (like thyroid cancer) are not confirmed in humans.

Be aware of rare but serious side effects like pancreatitis, gallbladder disease, and worsening of diabetic retinopathy (especially if you have pre-existing eye disease). While the risk of thyroid cancer is a concern in animal studies, no human cases have been confirmed. Report any severe abdominal pain or vision changes to your doctor.

Topical cosmetic peptides (e.g., GHK-Cu, Matrixyl, Argirelin) reduce wrinkles and improve skin firmness with excellent safety profiles, though effects are modest and require consistent long-term use.

Topical peptides like GHK-Cu, Matrixyl, and Argirelin can help reduce wrinkles and improve skin firmness when applied consistently over 8-12 weeks. They are generally safe and well-tolerated, but the effects are modest compared to injectable treatments. Regular use is necessary to maintain benefits.

High-dose tirzepatide (10–15 mg/week) is associated with a statistically significant increase in the risk of acute kidney injury (AKI) compared to control treatments.

If you are prescribed high-dose tirzepatide (10-15 mg/week), be aware of a small but statistically significant increased risk of acute kidney injury. Stay well-hydrated, especially if you experience gastrointestinal side effects like nausea or diarrhea, as volume depletion can trigger AKI. Monitor your kidney function as recommended by your doctor, and report any sudden changes in urination or swelling immediately.

In routine clinical practice, sporadic individual dietary consultations do not significantly improve adherence to the Mediterranean diet in patients with type 2 diabetes.

If you have type 2 diabetes, simply attending a dietitian appointment once or twice a year is unlikely to change your diet significantly. To get results, you need intensive, ongoing support that provides concrete tools and food, not just sporadic advice. If you feel you already know how to eat well, focus on maintaining that consistency rather than seeking more general advice.

In Korean adults, adherence to a low-carbohydrate diet (LCD) is associated with higher odds of metabolic syndrome, primarily because LCDs in this population often substitute refined carbohydrates with processed meats and animal fats rather than healthy unsaturated fats.

If you are Korean or have an East Asian metabolic profile, simply reducing carbohydrates may not lower your metabolic syndrome risk and could potentially increase it if you replace rice with processed meats or unhealthy fats. Focus on the quality of your diet—choosing whole grains, unsaturated fats, and lean proteins—rather than just cutting carbs.

There is no significant difference between various macronutrient dietary groups (VLCLP, MCLP, MCHP, etc.) in their ability to lower blood glucose, blood pressure, or total cholesterol compared to a moderate fat-low protein (MFLP) control diet.

Do not expect that switching to a specific macronutrient ratio (like Keto or Low Fat) will significantly lower your blood pressure, blood glucose, or total cholesterol compared to a standard moderate-fat diet. The evidence for these specific outcomes is weak and shows no clear winner among the diets studied.

Chronic low-grade inflammation and oxidative stress in MASLD drive atrial structural and electrical remodeling, creating an arrhythmogenic substrate for AF.

Treating MASLD involves more than just liver health; it requires addressing systemic inflammation and oxidative stress to protect the heart from structural remodeling that leads to AF.

Encapsulation techniques (e.g., spray drying, coacervation) protect probiotics from environmental stressors (heat, acid, oxidation) during production, storage, and gastrointestinal transit.

Look for probiotic products that mention 'encapsulation' or 'delayed release.' This technology helps the bacteria survive stomach acid so they can reach your intestines where they are needed.

Implantation of alginate-encapsulated engineered HEKGLP-1 cells in mice, activated by endogenous or exogenous melatonin, produces GLP-1 specifically during the night phase, restoring normoglycemia in type-2 diabetic models.

This research proposes a future therapy where genetically engineered cells are implanted and protected in a capsule. These cells produce the diabetes drug GLP-1 only when melatonin levels are high (at night). Patients could take oral melatonin to control how much GLP-1 is produced, potentially allowing for once-daily dosing instead of weekly injections. This is currently only proven in mice.

In obese patients without preexisting osteoarthritis, GLP-1 receptor agonist use is associated with an increased incidence of new hip and knee OA diagnoses and conversion to total knee arthroplasty within one year.

If you are obese but do not have existing hip or knee osteoarthritis, using a GLP-1 receptor agonist is associated with a higher risk of being diagnosed with new OA or needing knee replacement surgery within a year. This is unexpected given the weight loss benefits, and researchers suggest it might be due to increased physical activity stressing the joints. If you are considering these medications, discuss your joint health history with your doctor, and be aware that the benefits for joint health may primarily apply to those who already have OA.

The proposed mechanism for this hearing loss is the suppression of matrix metalloproteinase-9 (MMP-9) by exendin-4 derivatives, leading to micro-platelet-erythrocyte clot formation and occlusion of cochlear micro-circulation.

This mechanism is currently theoretical. While it provides a plausible biological explanation for why Lixisenatide might affect hearing, it has not been directly proven in human trials yet.

Tirzepatide (TZP) administration causes bone loss in obese diabetic mice by reducing gut microbiota biodiversity, specifically depleting Lachnospiraceae, which leads to lower levels of the metabolite evodiamine and subsequent increased osteoclastogenesis.

If you are taking Tirzepatide for diabetes or obesity, be aware that it may reduce bone density in your hips/femurs by altering gut bacteria. Discuss bone health monitoring with your doctor. The study suggests that maintaining gut health (specifically Lachnospiraceae bacteria) might protect bone, though probiotic supplementation is not yet a standard prescription.